By Sherri Oslick —

About
Court Report:  Each week we will report briefly on recently filed
biotech and pharma cases, and a few interesting cases will be selected
for periodic monitoring.

The Medicines Company v. PLIVA-HRVATSKA d.o.o. et al.
1:09-cv-00751; filed October 8, 2009 in the
District Court of Delaware

• Plaintiff:  The Medicines Company
• Defendants:  PLIVA-HRVATSKA d.o.o.; PLIVA d.d.;
Barr Laboratories Inc.; Barr Pharmaceuticals Inc.; Barr Pharmaceuticals, LLC;
Teva Pharmaceuticals Industries Ltd.; Teva Pharmaceuticals USA Inc.

Infringement of U.S. Patent No. 7,582,727 ("Pharmaceutical
Formulations of Bivalirudin and Process of Making the Same," issued
September 1, 2009) following a Paragraph IV certification as part of defendants'
filing of an ANDA to manufacture a generic version of The Medicines Company's
Angiomax® (bivalirudin, used as an anticoagulant in patients with unstable
angina undergoing percutaneous translurninal coronary angioplasty).  View the complaint here.

Glaxo Group Ltd. et al. v. Genentech, Inc. et al.
0:09-cv-61608; filed October 8, 2009 in the
Southern District of Florida

• Plaintiffs:  Glaxo Group Ltd.; SmithKline
Beecham Corp.
• Defendants:  Genentech, Inc.; City of Hope

Declaratory judgment of invalidity and
non-infringement of U.S. Patent No. 6,331,415 ("Methods of
Immunoglobulins, Vectors, and Transformed Host Cells for Use Therein,"
issued December 18, 2001) based on GSK's manufacture and sale of its Arzerra
product (ofatumumab, used to treat chronic lymphocytic leukemia).  View the complaint here.

Pfizer Inc. et al. v. Sandoz Inc.
1:09-cv-02392; filed October 7, 2009 in the
District Court of Colorado

• Plaintiffs:  Pfizer Inc.; Pfizer Pharmaceuticals,
LLC; Pfizer Ireland Pharmaceuticals; Pfizer Ltd.; C.P. Pharmaceuticals
International C.V.
• Defendant:  Sandoz Inc.

Pfizer Inc. et al. v. Sandoz Inc.
1:09-cv-00742; filed October 6, 2009 in the
District Court of Delaware

• Plaintiffs:  Pfizer Inc.; Pfizer Pharmaceuticals
LLC; Pfizer Ireland Pharmaceuticals; Pfizer Ltd.; CP Pharmaceuticals
International CV
• Defendant:  Sandoz Inc.

The complaints in these cases are substantially
identical.  Infringement of U.S.
Patent No. 6,455,574 ("Therapeutic Combination," issued September 24,
2002) following a Paragraph IV certification as part of Sandoz's filing of an
ANDA to manufacture a generic version of Pfizer's Caduet® (atorvastatin calcium — the active ingredient in Lipitor® — and amlodipine besylate — the active
ingredient in Norvasc® — used to treat high cholesterol in combination with
treating hypertension, angina, and/or coronary artery disease).  View the Colorado complaint here.

Elan Pharma International Ltd. et al. v. Actavis Elizabeth
LLC et al.
1:09-cv-00744; filed October 6, 2009 in the
District Court of Delaware

• Plaintiffs:  Elan Pharma International Ltd.;
Jazz Pharmaceuticals Inc.
• Defendants:  Actavis Elizabeth LLC; Anchen
Pharmaceuticals Inc.; Anchen Inc.

Infringement of U.S. Patent No. 7,456,462 ("Multiparticulate
Controlled Release Selective Serotonin Reuptake Inhibitor Formulations,"
issued December 16, 2008) following a Paragraph IV certification as part of
Actavis' filing of an ANDA to manufacture a generic version of Jazz's Luvox® CR
(fluvoxamine maleate, used to treat social anxiety disorder and obsessive
compulsive disorder).  View the
complaint here.

Teva Women's Health, Inc. v. Lupin, Ltd. et al.
3:09-cv-05112; filed October 6, 2009 in the
District Court of Delaware

• Plaintiff:  Teva Women's Health, Inc.
• Defendants:  Lupin, Ltd.; Lupin Pharmaceuticals,
Inc.

Infringement of U.S. Patent No. RE39,861 ("Methods
of Extended Use Oral Contraception," issued September 25, 2007) following
a Paragraph IV certification as part of Lupin's filing of an ANDA to
manufacture a generic version of Teva's Seasonale® (ethinyl estradiol and
levonorgestrel, used as oral contraception).  View the complaint here.

Boehringer Ingelheim Pharma GmbH
& Co. KG et al. v. Kappos
1:09-cv-01885; filed October 2, 2009 in the
District Court of the District of Columbia

• Plaintiffs:  Boehringer Ingelheim Pharma GmbH
& CO. KG; Boehringer Ingelheim International GmbH; Boehringer Ingelheim
Pharmaceuticals, Inc.
• Defendant:  David Kappos

Review and correction of the patent term adjustment
calculation made by the U.S. Patent and Trademark Office for U.S. Patent No.
7,514,557 ("Process for Preparing Acyclic HCV Protease Inhibitors,"
issued April 7, 2009).  View the
complaint here.

Apotex, Inc. et al. v. Sanofi Aventis et al.
0:09-cv-61575; filed October 2, 2009 in the
Southern District of Florida

• Plaintiffs:  Apotex Corp.; Apotex, Inc.
• Defendants:  Sanofi Aventis; Sanofi-Synthelabo,
Inc.; Bristol-Myers Squibb Co.; Bristol-Myers Squibb Sanofi-Pharmaceuticals
Holding Partnership

Declaratory judgment of unenforceability of U.S.
Patent No. 4,847,265 ("4,5-dihydro and
4,5,6,7-tetrahydropyrazolo(1,5-A)-pyrimidines" issued July 11, 1989) based
on defendants' failure to report all information to the FTC relating to a license
agreement between the parties regarding Plavix ® (clopidogrel bisulfate, used
for the reduction of atherothrombotic events).  View the complaint here.